Compare Advance Auto Parts, Inc. (AAP) vs Abeona Therapeutics Inc (ABEO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Abeona Therapeutics Inc — how do they compare? Advance Auto Parts, Inc. trades at $54.94 (market cap $3.37B), while Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M). The key difference: Advance Auto Parts, Inc. is far larger — about 9× Abeona Therapeutics Inc's market cap, and Advance Auto Parts, Inc. pays a 1.79% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AAP | ABEO | |
|---|---|---|
Market Cap | $3.37B | $373.32M |
Sector | Consumer Cyclical | Health |
52-Week High | $66.50 | $7.23 |
52-Week Low | $38.75 | $4.17 |
Enterprise Value | $5.64B | $228.22M |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $55.86, down 9.22% today, reflecting recent pressure despite beating earnings estimates in three consecutive quarters. The stock shows a bearish technical signal with key support at $55 and resistance at $59. Fundamentally, revenue has declined from $11.2B in 2022 to $8.6B in 2025, though net income turned positive at $44M in 2025 after a loss in 2024. Recent news highlights a brand campaign and expanded delivery partnership with OneRail.
The outlook is mixed; analyst consensus is a Hold with a $60.89 price target, suggesting modest upside. Opportunities include margin expansion and turnaround progress, but risks involve competitive pressures, volatile cash flows, and high P/E ratio. Investor sentiment is cautious amid declining revenue trends.
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →
